Delving into the Latest Updates on 18F-FEPPA with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

[18F]FE-PBR28

Target

TSPO

Mechanism

TSPO modulators(Translocator protein modulators), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

Other Diseases

Active Indication

Diagnostic agents

Inactive Indication

Alzheimer DiseaseInflammationMultiple Sclerosis+ [1]

Originator Organization

University of Toronto

Active Organization

University of Toronto

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC22H21FN2O3

InChIKeyHCUHRHHLUUZJEQ-VNRZBHCFSA-N

CAS Registry1095267-92-7

The goal of this clinical trial is to learn about how asthma influences brain function. The main questions it aims to answer are:
* How airway inflammation in asthma affects the brain; and,
* Whether airway inflammation in asthma is related to symptoms of depression and anxiety
Over the course of 3 visits, participants will:
* Complete questionnaires
* Complete computer tasks
* Undergo allergy skin test and breathing tests
* Give two blood samples
* Give a sputum sample
* Complete brain imaging scans
Researchers will compare results between participants with asthma, and participants who do not have asthma.

Start Date06 Mar 2024

Sponsor / Collaborator

University of Wisconsin Madison

[+1]

NCT02130271 / CompletedNot ApplicableIIT

PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients

The purpose of this study is to see if the spine shows areas of inflammation using a specific type of imaging (pictures).

Start Date01 Apr 2014

Sponsor / Collaborator

The General Hospital Corp.

NCT02095639 / TerminatedNot ApplicableIIT

Does Electroconvulsive Therapy Cause Neuroinflammation? An [18F]FEPPA Positron Emission Tomography Study in Treatment Resistant Depression

The purpose of this study is to explore whether electroconvulsive therapy (ECT) accidentally leads to a side effect of brain inflammation. Patients with treatment resistant depression who are planning to take ECT will be subsequently approached to participate in the study.

Start Date01 Aug 2012

Sponsor / Collaborator

Centre for Addiction & Mental Health

100 Clinical Results associated with 18F-FEPPA

Login to view more data

100 Translational Medicine associated with 18F-FEPPA

Login to view more data

100 Patents (Medical) associated with 18F-FEPPA

Login to view more data

100 Deals associated with 18F-FEPPA

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 1	US	-	01 Aug 2009
Inflammation	Phase 1	US	-	01 Aug 2009
Multiple Sclerosis	Phase 1	US	-	01 Aug 2009
Parkinson Disease	Phase 1	US	-	01 Aug 2009
Diagnostic agents	Phase 1	-	University of Toronto	-